Article
Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.
The Lancet. Infectious diseases - 1 Jan 2015
Reddy K Rajender, Zeuzem Stefan, Zoulim Fabien, Weiland Ola, Horban Andrzej, Stanciu Carol, Villamil Federico Guillermo, Andreone Pietro, George Jacob, Dammers Elisabeth, Fu Min, Kurland Darryl, Lenz Oliver, Ouwerkerk-Mahadevan Sivi, Verbinnen Thierry, Scott Jane, Jessner Wolfgang
Abstract excerpt
BACKGROUND: We did a phase 3 study in previous non-responders with chronic hepatitis C virus (HCV) genotype 1 infection and compensated liver disease that related to the standard of care for these patients at the time this study was initiated. We investigated whether simeprevir is non-inferior in terms of efficacy to telaprevir, each in combination with peginterferon alfa-2a and ribavirin. METHODS: We did this...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.